Glucocorticoid signature of preterm infants developing bronchopulmonary dysplasia.
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
29
12
2022
accepted:
09
05
2023
revised:
04
04
2023
medline:
6
11
2023
pubmed:
25
6
2023
entrez:
24
6
2023
Statut:
ppublish
Résumé
Systemic inflammation plays a key role in the development of bronchopulmonary dysplasia (BPD). Cortisol is known to dampen inflammation. However, adrenal function following preterm birth is characterized by insufficient cortisol levels for the degree of inflammation, and a relative abundancy of cortisol precursors. We investigated whether this pattern could contribute to the development of BPD in preterm infants born <30 weeks of gestation. Cortisol, cortisone, 17-OH progesterone (17-OHP) and 11-deoxycortisol were measured in serum obtained at postnatal days 1, 3, 7, 14 and 28, using liquid-chromatography-tandem-mass-spectrometry. The presence of BPD was ascertained at 36 weeks postmenstrual age. Sixty-five infants were included for analysis, of whom 32 (49%) developed BPD. Preterm infants developing BPD, as compared to those without BPD, had higher levels of 17-OHP, 11-deoxycortisol and cortisone relative to cortisol in their first week of life, but not at birth or beyond day 7. Preterm infants developing BPD had higher levels of cortisol precursors and cortisone relative to cortisol in their first week of life than infants without BPD. These findings suggest that BPD is preceded by an activated hypothalamus-pituitary-adrenal axis that could not meet the high cortisol demands, which may predispose to inflammation and BPD. Relative adrenal insufficiency is common in the first weeks after preterm birth, resulting in insufficient cortisol production for the degree of inflammation and a relative abundance of cortisol precursors; Whether this pattern contributes to the development of bronchopulmonary dysplasia (BPD) is not fully elucidated, since most studies focused on cortisol levels; Preterm infants developing BPD had higher levels of cortisol precursors and cortisone relative to cortisol in the first week of life, suggestive of a hypothalamus-pituitary-adrenal-axis activation during BPD development which cannot meet the high cortisol demands in tissues; This glucocorticoid pattern is likely to dispose to inflammation and BPD.
Sections du résumé
BACKGROUND
Systemic inflammation plays a key role in the development of bronchopulmonary dysplasia (BPD). Cortisol is known to dampen inflammation. However, adrenal function following preterm birth is characterized by insufficient cortisol levels for the degree of inflammation, and a relative abundancy of cortisol precursors. We investigated whether this pattern could contribute to the development of BPD in preterm infants born <30 weeks of gestation.
METHODS
Cortisol, cortisone, 17-OH progesterone (17-OHP) and 11-deoxycortisol were measured in serum obtained at postnatal days 1, 3, 7, 14 and 28, using liquid-chromatography-tandem-mass-spectrometry. The presence of BPD was ascertained at 36 weeks postmenstrual age.
RESULTS
Sixty-five infants were included for analysis, of whom 32 (49%) developed BPD. Preterm infants developing BPD, as compared to those without BPD, had higher levels of 17-OHP, 11-deoxycortisol and cortisone relative to cortisol in their first week of life, but not at birth or beyond day 7.
CONCLUSION
Preterm infants developing BPD had higher levels of cortisol precursors and cortisone relative to cortisol in their first week of life than infants without BPD. These findings suggest that BPD is preceded by an activated hypothalamus-pituitary-adrenal axis that could not meet the high cortisol demands, which may predispose to inflammation and BPD.
IMPACT
Relative adrenal insufficiency is common in the first weeks after preterm birth, resulting in insufficient cortisol production for the degree of inflammation and a relative abundance of cortisol precursors; Whether this pattern contributes to the development of bronchopulmonary dysplasia (BPD) is not fully elucidated, since most studies focused on cortisol levels; Preterm infants developing BPD had higher levels of cortisol precursors and cortisone relative to cortisol in the first week of life, suggestive of a hypothalamus-pituitary-adrenal-axis activation during BPD development which cannot meet the high cortisol demands in tissues; This glucocorticoid pattern is likely to dispose to inflammation and BPD.
Identifiants
pubmed: 37355738
doi: 10.1038/s41390-023-02690-3
pii: 10.1038/s41390-023-02690-3
doi:
Substances chimiques
Glucocorticoids
0
Hydrocortisone
WI4X0X7BPJ
Cortisone
V27W9254FZ
Cortodoxone
WDT5SLP0HQ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1804-1809Informations de copyright
© 2023. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.
Références
Ambalavanan, N. et al. Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants. Pediatrics 123, 1132–1141 (2009).
doi: 10.1542/peds.2008-0526
pubmed: 19336372
Finken, M. J. J. et al. Programming of the hypothalamus-pituitary-adrenal axis by very preterm birth. Ann. Nutr. Metab. 70, 170–174 (2017).
doi: 10.1159/000456040
pubmed: 28301846
Kamrath, C., Hartmann, M. F., Boettcher, C. & Wudy, S. A. Reduced Activity of 11beta-Hydroxylase Accounts for Elevated 17alpha-Hydroxyprogesterone in Preterms. J. Pediatr. 165, 280–284 (2014).
doi: 10.1016/j.jpeds.2014.04.011
pubmed: 24862381
Pijnenburg-Kleizen, K. J. et al. Adrenal Steroid Metabolites Accumulating in Congenital Adrenal Hyperplasia Lead to Transactivation of the Glucocorticoid Receptor. Endocrinology 156, 3504–3510 (2015).
doi: 10.1210/en.2015-1087
pubmed: 26207344
Stewart, P. M., Murry, B. A. & Mason, J. I. Type 2 11 Beta-Hydroxysteroid Dehydrogenase in Human Fetal Tissues. J. Clin. Endocrinol. Metab. 78, 1529–1532 (1994).
pubmed: 8200959
Watterberg, K. L., Scott, S. M., Backstrom, C., Gifford, K. L. & Cook, K. L. Links between Early Adrenal Function and Respiratory Outcome in Preterm Infants: Airway Inflammation and Patent Ductus Arteriosus. Pediatrics 105, 320–324 (2000).
doi: 10.1542/peds.105.2.320
pubmed: 10654949
Renolleau, C. et al. Association between Baseline Cortisol Serum Concentrations and the Effect of Prophylactic Hydrocortisone in Extremely Preterm Infants. J. Pediatr. 234, 65–70 e63 (2021).
doi: 10.1016/j.jpeds.2020.12.057
pubmed: 33359303
Watterberg, K. L. & Scott, S. M. Evidence of early Adrenal insufficiency in babies who develop bronchopulmonary dysplasia. Pediatrics 95, 120–125 (1995).
doi: 10.1542/peds.95.1.120
pubmed: 7770288
Watterberg, K. L. et al. Effect of Dose on Response to Adrenocorticotropin in extremely low birth weight infants. J. Clin. Endocrinol. Metab. 90, 6380–6385 (2005).
doi: 10.1210/jc.2005-0734
pubmed: 16159938
Watterberg, K. L., Gerdes, J. S. & Cook, K. L. Impaired Glucocorticoid synthesis in premature infants developing chronic lung disease. Pediatr. Res 50, 190–195 (2001).
doi: 10.1203/00006450-200108000-00005
pubmed: 11477202
Finken, M. J. et al. Glucocorticoid programming in very preterm birth. Horm. Res. Paediatr. 85, 221–231 (2016).
doi: 10.1159/000443734
pubmed: 26943327
Doyle, L. W., Cheong, J. L., Ehrenkranz, R. A. & Halliday, H. L. Early (<8 Days) Systemic Postnatal Corticosteroids for Prevention of Bronchopulmonary Dysplasia in Preterm Infants. Cochrane Database Syst. Rev. 10, CD001146 (2017).
pubmed: 29063585
Doyle, L. W., Cheong, J. L., Hay, S., Manley, B. J. & Halliday, H. L. Early (≪7 Days) Systemic Postnatal Corticosteroids for Prevention of Bronchopulmonary Dysplasia in Preterm Infants. Cochrane Database Syst. Rev. 10, CD001146 (2021).
pubmed: 34674229
Singh, N. & Gautham, K. S. Pattern of Postnatal Steroid Use for Bronchopulmonary Dysplasia in Extremely Preterm Infants. J. Perinatol. 42, 1258–1259 (2022).
doi: 10.1038/s41372-022-01353-1
pubmed: 35264697
Yao, S. et al. Postnatal Corticosteroid Use for Prevention or Treatment of Bronchopulmonary Dysplasia in England and Wales 2012-2019: A Retrospective Population Cohort Study. BMJ Open 12, e063835 (2022).
doi: 10.1136/bmjopen-2022-063835
pubmed: 36396314
pmcid: 9676997
Doyle, L. W., Halliday, H. L., Ehrenkranz, R. A., Davis, P. G. & Sinclair, J. C. An Update on the Impact of Postnatal Systemic Corticosteroids on Mortality and Cerebral Palsy in Preterm Infants: Effect Modification by Risk of Bronchopulmonary Dysplasia. J. Pediatr. 165, 1258–1260 (2014).
doi: 10.1016/j.jpeds.2014.07.049
pubmed: 25217197
Onland, W. et al. Clinical Prediction Models for Bronchopulmonary Dysplasia: A Systematic Review and External Validation Study. BMC Pediatr. 13, 207 (2013).
doi: 10.1186/1471-2431-13-207
pubmed: 24345305
pmcid: 3878731
Romijn, M. et al. Prediction Models for Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review and Meta-Analysis. J. Pediatr. 113370 (2023). https://doi.org/10.1016/j.jpeds.2023.01.024 . Epub ahead of print.
Jobe, A. H. The New Bronchopulmonary Dysplasia. Curr. Opin. Pediatr. 23, 167–172 (2011).
doi: 10.1097/MOP.0b013e3283423e6b
pubmed: 21169836
pmcid: 3265791
Fanelli, F. et al. Report from the Harmoster Study: Impact of Calibration on Comparability of Lc-Ms/Ms Measurement of Circulating Cortisol, 17oh-Progesterone and Aldosterone. Clin. Chem. Lab Med 60, 726–739 (2022).
doi: 10.1515/cclm-2021-1028
pubmed: 35172417
Aoki, M., Urakami, T., Nagano, N., Aoki, R. & Morioka, I. Association of Plasma Cortisol Levels with Gestational Age and Anthropometric Values at Birth in Preterm Infants. Int J. Environ. Res Public Health 19, 11448 (2022).
doi: 10.3390/ijerph191811448
pubmed: 36141720
pmcid: 9517663
Stoll, B. J. et al. Neonatal Outcomes of Extremely Preterm Infants from the Nichd Neonatal Research Network. Pediatrics 126, 443–456 (2010).
doi: 10.1542/peds.2009-2959
pubmed: 20732945
Hoftiezer, L. et al. From Population Reference to National Standard: New and Improved Birthweight Charts. Am. J. Obstet. Gynecol. 220, 383 e381–383 e317 (2019).
doi: 10.1016/j.ajog.2018.12.023
Banks, B. A. et al. Association of Plasma Cortisol and Chronic Lung Disease in Preterm Infants. Pediatrics 107, 494–498 (2001).
doi: 10.1542/peds.107.3.494
pubmed: 11230588
Nykanen, P., Anttila, E., Heinonen, K., Hallman, M. & Voutilainen, R. Early Hypoadrenalism in Premature Infants at Risk for Bronchopulmonary Dysplasia or Death. Acta Paediatr. 96, 1600–1605 (2007).
doi: 10.1111/j.1651-2227.2007.00500.x
pubmed: 17888053
Pau, D. A., Mackley, A. & Bartoshesky, L. Newborn Screening Levels of 17-Hydroxyprogesterone in Very Low Birth Weight Infants and the Relationship to Chronic Lung Disease. J. Pediatr. Endocrinol. Metab. 19, 1119–1124 (2006).
pubmed: 17128559
Merz, U., Pfaffle, R., Peschgens, T. & Hornchen, H. The Hypothalamic-Pituitary-Adrenal Axis in Preterm Infants Weighing < or = 1250 G: Association with Perinatal Data and Chronic Lung Disease. Acta Paediatr. 87, 313–317 (1998).
doi: 10.1111/j.1651-2227.1998.tb01444.x
pubmed: 9560040
Bolt, R. J. et al. Maturity of the Adrenal Cortex in Very Preterm Infants Is Related to Gestational Age. Pediatr. Res 52, 405–410 (2002).
doi: 10.1203/00006450-200209000-00017
pubmed: 12193676
Engels, M. et al. Glucocorticoid Activity of Adrenal Steroid Precursors in Untreated Patients with Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab 104, 5062–72 (2019).
Ng, P. C. et al. Transient Adrenocortical Insufficiency of Prematurity and Systemic Hypotension in Very Low Birthweight Infants. Arch. Dis. Child Fetal Neonatal Ed. 89, F119–F126 (2004).
doi: 10.1136/adc.2002.021972
pubmed: 14977894
pmcid: 1756043
Krasowski, M. D. et al. Cross-Reactivity of Steroid Hormone Immunoassays: Clinical Significance and Two-Dimensional Molecular Similarity Prediction. BMC Clin. Pathol. 14, 33 (2014).
doi: 10.1186/1472-6890-14-33
pubmed: 25071417
pmcid: 4112981
Agrawal, N., Chakraborty, P. P., Sinha, A. & Maiti, A. False Elevation of Serum Cortisol in Chemiluminescence Immunoassay by Siemens Advia Centaur Xp System in 21-Hydroxylase Deficiency: An ‘Endocrine Laboma’. BMJ Case Rep. 13, e235450 (2020).
doi: 10.1136/bcr-2020-235450
pubmed: 32900728
pmcid: 7477984
Haddad, R. A., Giacherio, D. & Barkan, A. L. Interpretation of Common Endocrine Laboratory Tests: Technical Pitfalls, Their Mechanisms and Practical Considerations. Clin. Diabetes Endocrinol. 5, 12 (2019).
doi: 10.1186/s40842-019-0086-7
pubmed: 31367466
pmcid: 6657094
Julious, S. A. Sample Sizes for Clinical Trials 317 (Chapman and Hall/CRC, 2010).
Chow, S,-C,, W. H., Shao, J,. Sample Size Calculations in Clinical Research 480 (Chapman and Hall/CRC, 2007).
Machin, D., C M. J., Tan, S. B., Tan, S. H. Sample Size Tables for Clinical Studies 2 edn(Wiley-Blackwell Science, 1997).
Zar, J. H. Biostatistical Analysis 2 edn(Practice-Hall, 1984).
Ng, P. C. et al. Early Pituitary-Adrenal Response and Respiratory Outcomes in Preterm Infants. Arch. Dis. Child Fetal Neonatal Ed. 89, F127–F130 (2004).
doi: 10.1136/adc.2002.021980
pubmed: 14977895
pmcid: 1756036